Literature DB >> 15796768

Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol-responsive cells within the hypothalamus.

T A Richter1, J E Robinson, J M Lozano, N P Evans.   

Abstract

Elevated oestradiol concentrations during the follicular phase stimulate a surge in gonadotropin-releasing hormone (GnRH) and luteinising hormone (LH) concentrations, which leads to ovulation. Progesterone can block the oestradiol-induced GnRH/LH surge, but the mechanism that is involved is unclear. We examined the effect of progesterone on oestradiol-induced activation of cells within the ovine hypothalamus/preoptic area (POA) to determine: (i) in which regions progesterone acts to block the GnRH/LH surge and (ii) whether progesterone directly or indirectly prevents activation of oestradiol-responsive cells. Cellular activation was assessed by measuring the number of cells that expressed Fos (an immediate early gene). Exposure to increased oestradiol concentrations in the absence of progesterone (which normally stimulates a LH surge) did not cause any region-specific changes in hypothalamic Fos expression during the activation stage of the LH surge-induction process (Experiment 1). The same treatment significantly increased cellular activation within the POA, lateral septum (LS), and arcuate nucleus at the time of surge onset (Experiment 2). Concurrent exposure to increased oestradiol and progesterone concentrations during the activation stage of the surge-induction process (which normally blocks the LH surge) was associated with significantly reduced cellular activation within the ventromedial hypothalamus and anterior hypothalamic area, relative to the positive controls (oestradiol increment alone) and arcuate nucleus relative to the negative controls (no increment in oestradiol) during the activation stage (Experiment 1). At the time of surge onset (Experiment 2), exposure to progesterone during the activation period prevented the oestradiol-induced increase in cellular activation that occurred in the POA, LS and arcuate nucleus of the positive controls. These results demonstrated that oestradiol and progesterone induced differential region- and time-specific effects on cellular activation within the regions of the ovine brain that generate the preovulatory GnRH/LH surge. Moreover, the lack of cellular activation within the POA, LS and arcuate nucleus at the time of surge onset in animals exposed to progesterone during the activation stage is consistent with the hypothesis that progesterone can block the preovulatory surge by direct inhibition of oestradiol-induced cellular activation in these areas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15796768     DOI: 10.1111/j.1365-2826.2005.01287.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  11 in total

1.  Distribution of mRNAs encoding classical progestin receptor, progesterone membrane components 1 and 2, serpine mRNA binding protein 1, and progestin and ADIPOQ receptor family members 7 and 8 in rat forebrain.

Authors:  K A Intlekofer; S L Petersen
Journal:  Neuroscience       Date:  2010-10-25       Impact factor: 3.590

2.  Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release.

Authors:  Nicole Sleiter; Yefei Pang; Cheryl Park; Teresa H Horton; Jing Dong; Peter Thomas; Jon E Levine
Journal:  Endocrinology       Date:  2009-05-07       Impact factor: 4.736

3.  Prenatal Testosterone Treatment Leads to Changes in the Morphology of KNDy Neurons, Their Inputs, and Projections to GnRH Cells in Female Sheep.

Authors:  Maria Cernea; Vasantha Padmanabhan; Robert L Goodman; Lique M Coolen; Michael N Lehman
Journal:  Endocrinology       Date:  2015-06-10       Impact factor: 4.736

4.  Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study.

Authors:  Yin-Mei Chen; Qian-Rong Qi; Qing-Zhen Xie; Yi-Fan Yang; Yi Xia; Xiao-Dan Zhou
Journal:  Curr Med Sci       Date:  2018-06-22

5.  Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.

Authors:  Xiuxian Zhu; Xiaole Zhang; Yonglun Fu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

6.  An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders.

Authors:  Chen-Yu Huang; Guan-Yeu Chen; Miawh-Lirng Shieh; Hsin-Yang Li
Journal:  Reprod Biol Endocrinol       Date:  2018-03-05       Impact factor: 5.211

7.  Pilot Study to Evaluate the Association Between the Length of the Luteal Phase and Estrous Activity Detected by Automated Activity Monitoring in Dairy Cows.

Authors:  Jose Denis-Robichaud; Stephen J LeBlanc; Andria Jones-Bitton; Bruna F Silper; Ronaldo L Aoki Cerri
Journal:  Front Vet Sci       Date:  2018-08-31

8.  Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.

Authors:  Yun Wang; Yanping Kuang; Qiuju Chen; Renfei Cai
Journal:  Trials       Date:  2018-08-22       Impact factor: 2.279

9.  Comparison of the effects of Duphaston and Cetrotide on oocyte and embryo quality in women undergoing ICSI: A cross-sectional study.

Authors:  Niloofar Motaref; Sheyda Jouhari; Afsaneh Mohammadzadeh; Somaieh Kazemnejad; Narges Madadi; Sadaf Eghtedari; Abolfazl Ghoodjani
Journal:  Int J Reprod Biomed       Date:  2020-11-22

10.  Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: a prospective pilot study.

Authors:  Dan Nayot; Shany Klachook; Robert F Casper
Journal:  Reprod Biol Endocrinol       Date:  2013-02-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.